Sign in

You're signed outSign in or to get full access.

EH

ExlService Holdings, Inc. (EXLS)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered revenue of $501.0M (+14.8% YoY; +4.1% QoQ), GAAP diluted EPS of $0.40 (+38.3% YoY), and adjusted diluted EPS of $0.48 (+26.9% YoY), with margin expansion across gross and operating metrics .
  • EXL raised full-year 2025 revenue guidance to $2.035–$2.065B (from $2.025–$2.060B) while maintaining adjusted EPS guidance at $1.83–$1.89; CFO added color on FX tailwinds, ETR (22–23%), net interest expense (~$1M), and capex ($50–$55M) .
  • Results beat Wall Street consensus: revenue $501.0M vs $490.3M*, EPS $0.48 vs $0.441*; magnitude of beat was modest on revenue (+2.2%) and more pronounced on EPS (+8.8%)*. The company emphasized strong demand for data/AI-led solutions (53% of revenue) and pipeline strength .
  • Near-term stock catalysts: guidance raise, data/AI disclosure (53% of revenue), segment momentum in Healthcare/Life Sciences (+24.8% YoY), and Investor Strategy Update on May 6 discussing AI strategy and new operating model .

What Went Well and What Went Wrong

What Went Well

  • Data/AI execution: Management reported data and AI-led revenue grew 16% YoY and reached 53% of total revenue; launched excelerate.ai agentic AI platform to embed AI agents into workflows, with strong customer traction .
  • Margin expansion: Gross margin rose to 38.6% (+120 bps YoY), GAAP operating margin to 15.7% (+160 bps YoY), and adjusted operating margin to 20.1% (+120 bps YoY), underscoring operating leverage and improved mix .
  • Healthcare strength: Healthcare & Life Sciences segment revenue grew to $125.6M (+24.8% YoY; +11.4% QoQ), driven by higher volumes in payment services and expansion with existing clients .

Management quotes:

  • CEO: “We are pleased with our first quarter results and strong start to the year, as we delivered revenue and adjusted diluted EPS growth of 15% and 27% respectively.”
  • CFO: “We are increasing our revenue guidance for the year, based on our business momentum and more favorable currency exchange rates.”

What Went Wrong

  • Insurance growth deceleration: Insurance grew 8.7% YoY in Q1 (new segments), below company average, with management attributing to timing and expecting improvement later in the year .
  • Sequential margin cadence: Management flagged stepped-up investments in data/AI through the year, implying adjusted operating margin will settle below Q1’s 20.1% and average ~19.5–19.6% for FY25 (10–20 bps YoY improvement) .
  • Macro and pricing pressure: Management noted increased macro uncertainty and competitive pricing dynamics, though diversified annuity-like revenue base provides resilience .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Millions)$472.1 $481.4 $501.0
GAAP Diluted EPS ($)$0.33 $0.31 $0.40
Adjusted Diluted EPS ($)$0.44 $0.44 $0.48
Gross Margin %37.8% 38.1% 38.6%
Operating Margin % (GAAP)14.7% 14.8% 15.7%
Adjusted Operating Margin %19.9% 18.8% 20.1%
Adjusted EBITDA ($USD Millions)$104.4 $102.9 $111.2
Adjusted EBITDA Margin %22.1% 21.4% 22.2%

Segment breakdown (new reporting segments; prior period recast):

SegmentQ1 2024 Revenue ($M)Q1 2025 Revenue ($M)Q1 2024 GM%Q1 2025 GM%
Insurance$158.3 $172.0 33.8% 36.6%
Healthcare & Life Sciences$100.7 $125.6 45.3% 43.9%
Banking, Capital Markets & Diversified Industries$103.2 $117.7 36.1% 37.3%
International Growth Markets$74.3 $85.7 35.9% 36.6%
Total$436.5 $501.0 37.4% 38.6%

KPIs

KPIQ1 2025
Data & AI-led revenue (% of total)53%
New clients (count)10
Cash incl. short- and long-term investments ($M)$346
Revolver debt ($M)$307
Net cash position ($M)$39
Cash from operations ($M)$3
Capex ($M)$13
Share repurchases ($M)$8
Effective tax rate (%)22.3%

Results vs Wall Street consensus (S&P Global)

Metric (Q1 2025)ConsensusActualSurprise ($ / %)
Revenue ($M)490.3*501.0 +$10.7 / +2.18%*
Primary EPS ($)0.441*0.480 +$0.0388 / +8.79%*
# of Estimates (Revenue/EPS)8 / 8*——

Values marked with * retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue ($B)FY 2025$2.025–$2.060 $2.035–$2.065 Raised (midpoint +$7M)
Adjusted diluted EPS ($)FY 2025$1.83–$1.89 $1.83–$1.89 Maintained
Adjusted operating margin (YoY bps)FY 2025—+10–20 bps New color (expansion)
FX gain ($M)FY 2025~1 ~2–3 Raised
Net interest expense ($M)FY 2025~1 ~1 Maintained
Effective tax rate (%)FY 202522–23 22–23 Maintained
Capex ($M)FY 202550–55 50–55 Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024, Q4 2024)Current Period (Q1 2025)Trend
AI/technology initiativesLaunched Insurance LLM; expanded Databricks; accelerating analytics and digital ops ; Announced EXLerate.AI agentic platform; deep partner ecosystem; 100+ accelerators excelerate.ai agentic platform launched; 15+ industry-specific agents in production; robust client adoption Accelerating
Data & AI-led revenue53% of 2024 revenue; plan to report AI revenue alongside segments 53% of Q1 revenue; +16% YoY growth Stable-high, growing
Macro/pricingCautious outlook; investment required to drive AI; pricing competitive More macro uncertainty; prudent stance; pricing pressure acknowledged Increasing caution
Healthcare & Life SciencesStrong momentum in payment services and clinical services $125.6M (+24.8% YoY; +11.4% QoQ) Accelerating
Insurance verticalDouble-digit growth in prior quarters +8.7% YoY (segment); management views deceleration as timing; expects in-line with company in 2025 Slight deceleration near-term
International Growth MarketsFocus and contribution rising; expanding globally $85.7M (+17% YoY); ~17% of revenue Expanding
Client visibilityPipeline up; large deals increasing ~87% committed revenue, ~95% visibility at guidance midpoint Strong visibility maintained

Management Commentary

  • Strategic focus: “Beginning with the first quarter… we will be reporting data and AI-led revenue on a quarterly basis… represented 53% of total revenue” .
  • Platform launch: “During the quarter, we launched excelerate.ai, our Agentic AI platform… deploy AI much more quickly… significantly lower cost resulting in substantial ROI” .
  • Insurance outlook: “We don’t think [lower Q1 insurance growth] is an issue… expect the growth rate… to increase… don’t really read much into that” .
  • Investment cadence: “We anticipate increased investments in data and AI… continue to anticipate adjusted operating profit margin improvement of 10 to 20 basis points for the full year” .
  • Revenue visibility: “We have about 87% committed… and right around 95% visibility overall at the midpoint” .

Q&A Highlights

  • Revenue visibility: CFO cited ~87% committed revenue and ~95% visibility at midpoint, supporting confidence in FY25 trajectory .
  • AI economics and cannibalization: CEO expects “human in the loop,” rising revenue per head, and gradual labor change; proactive cannibalization drives faster client adoption and growth .
  • Segment cadence and margins: Management guided stronger 1H vs 2H due to tougher comps and noted higher AI investment through Q2–Q4, implying margins below Q1’s peak but up 10–20 bps YoY for FY25 .
  • Competitive landscape and pricing: Competes with startups, hyperscalers, and tech firms; differentiation from domain/workflow/data mastery; acknowledged pricing pressure in slower macro .
  • Healthcare momentum: Sequential strength (+11% QoQ) driven by new clients and service-line growth; viewed as large vertical opportunity .

Estimates Context

  • Q1 2025 beat vs consensus*: revenue $501.0M vs $490.3M* (+$10.7M; +2.18%), EPS $0.48 vs $0.441 (+$0.0388; +8.79%). Eight estimates for both revenue and EPS .
  • Implications: Modest top-line beat and stronger EPS beat suggest operating leverage and mix/margin benefits; estimate revisions likely focus on Healthcare/Life Sciences strength and updated FX assumptions following guidance raise* .

Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • EXL delivered a clean beat and raised full-year revenue guidance, with margin expansion and strong Healthcare/Life Sciences growth, reinforcing demand for data/AI-led solutions (53% of revenue) .
  • Expect FY25 margins to average ~19.5–19.6% (adjusted operating), below Q1’s 20.1% near-term due to stepped-up AI investments; longer-term margin trajectory remains upward (+10–20 bps YoY) with pricing on higher-value services .
  • Insurance grew slower in Q1 under new segments but management expects reacceleration; watch segment updates and recast disclosures for comparability .
  • Strong revenue visibility (~87% committed; ~95% overall) reduces execution risk in a choppy macro; pipeline of larger integrated deals continues to expand .
  • Near-term catalysts: May 6 Investor Strategy Update (deeper dive on AI and operating model), ongoing disclosure of data/AI revenue, and quarterly reporting of agentic AI progress .
  • Monitor pricing pressure and macro uncertainty; diversified annuity-like revenue and outcome-linked solutions mitigate risk; investment pace in AI is the key swing factor for margins and growth .
  • For trading, the guidance raise and EPS beat are positive; attention will center on sustainability of Healthcare momentum, normalization of Insurance growth, and margin cadence given heavier AI investment .